Research programme: autoimmune/inflammatory disease monoclonal antibody therapeutics - MacroGenics

Drug Profile

Research programme: autoimmune/inflammatory disease monoclonal antibody therapeutics - MacroGenics

Alternative Names: CD32B x CD79B; DART inflammation; Inflammation DART

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD79 antigen modulators; Fc gamma receptor IIB modulators; Lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 28 Apr 2018 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
  • 29 Sep 2014 MacroGenics and Takeda enter into a second license option agreement for up to four product candidates incorporating the DART® platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top